TipRanks on MSN
Amgen’s new study on maridebart cafraglutide: A potential game-changer in obesity treatment?
Amgen Inc ($AMGN) announced an update on their ongoing clinical study. Amgen Inc. is conducting a Phase 1 clinical study titled A Phase 1, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback